These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 19839928)
21. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990 [TBL] [Abstract][Full Text] [Related]
22. Pemetrexed in bladder, head and neck, and cervical cancers. Paz-Ares L; Ciruelos E; García-Carbonero R; Castellano D; Lopez-Martín A; Cortés-Funes H Semin Oncol; 2002 Dec; 29(6 Suppl 18):69-75. PubMed ID: 12571815 [TBL] [Abstract][Full Text] [Related]
23. Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation. Tanaka H; Horiike A; Sakatani T; Saito R; Yanagitani N; Kudo K; Ohyanagi F; Horai T; Nishio M Anticancer Drugs; 2015 Jun; 26(5):573-8. PubMed ID: 25714250 [TBL] [Abstract][Full Text] [Related]
24. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients. Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386 [TBL] [Abstract][Full Text] [Related]
25. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201 [TBL] [Abstract][Full Text] [Related]
26. Pemetrexed in advanced colorectal cancer. Louvet C; de Gramont A Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):56-62. PubMed ID: 15655939 [TBL] [Abstract][Full Text] [Related]
27. Molecular, biochemical, and cellular pharmacology of pemetrexed. Goldman ID; Zhao R Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805 [TBL] [Abstract][Full Text] [Related]
30. Phase II studies of pemetrexed in metastatic breast and gynecologic cancers. Smith I Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):63-5. PubMed ID: 15655940 [TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494 [TBL] [Abstract][Full Text] [Related]
32. The current state of pemetrexed in ovarian cancer. Miller RE; Banerjee S Expert Opin Investig Drugs; 2013 Sep; 22(9):1201-10. PubMed ID: 23899335 [TBL] [Abstract][Full Text] [Related]
33. The role of pemetrexed in the treatment of colorectal cancer. Hochster H Semin Oncol; 2002 Dec; 29(6 Suppl 18):54-6. PubMed ID: 12571812 [TBL] [Abstract][Full Text] [Related]
34. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines. Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354 [TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300 [TBL] [Abstract][Full Text] [Related]
37. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Sigmond J; Backus HH; Wouters D; Temmink OH; Jansen G; Peters GJ Biochem Pharmacol; 2003 Aug; 66(3):431-8. PubMed ID: 12907242 [TBL] [Abstract][Full Text] [Related]
38. Pemetrexed for the treatment of non-small cell lung cancer. Genova C; Rijavec E; Truini A; Coco S; Sini C; Barletta G; Dal Bello MG; Alama A; Savarino G; Pronzato P; Boccardo F; Grossi F Expert Opin Pharmacother; 2013 Aug; 14(11):1545-58. PubMed ID: 23683110 [TBL] [Abstract][Full Text] [Related]
39. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830 [TBL] [Abstract][Full Text] [Related]